Stiripentol gets TGA approval for Dravet syndrome

Stiripentol (Diacomit) has been listed by the TGA for treatment of seizures in infants associated with Dravet syndrome. The anticonvulsant has been added to the Australian Register of Therapeutic Goods for adjunctive treatment of generalised tonic-clonic and clonic seizures associated with severe myoclonic epilepsy in infancy in patients whose seizures are not adequately controlled with ...

Already a member?

Login to keep reading.

© 2022 the limbic